Two seasoned business leaders join the Board
QUEBEC CITY, Nov. 26, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
today announced that its Board of Directors has appointed two new
members, effective immediately. The new directors are Dr. Jacques
Simoneau, current President and Chief Executive Officer of Gestion
Univalor L.P. and Mr. Andrew J. Sheldon, current President and Chief
Executive Officer of Medicago. The two new directors will also stand
for re-election at DiagnoCure's next annual meeting of shareholders.
"The addition of these new directors will further diversify the
outstanding talents and wide-ranging experience that our directors
already bring to DiagnoCure," said Dr. Yves Fradet, the Chairman of the
Board. "Both are widely respected and experienced business leaders, and
together they will provide our board and management team with new
insight and perspectives relating to DiagnoCure's business and the
rapidly changing diagnostics industry."
These appointments are made in the context of the retirement from the
Board of Mr. Paul Gobeil, Mr. Alain Michel and Dr. Mario Thomas.
Dr. Thomas has stepped down in order to focus on his other professional
engagements while Messrs. Michel and Gobeil both say their decision is
motivated by their recognition of the need to foster renewal on the
Board.
"On behalf of DiagnoCure and its Board of Directors, we wish to thank
Mr. Gobeil, Mr. Michel and Dr. Thomas for their devoted service and
sound counsel, and we wish them the very best," said Dr. Yves Fradet,
in his capacity as Chairman of the Board.
Dr. Simoneau has agreed to join and to chair the Audit and Risk
Management Committee of the Corporation.
About Andrew (Andy) Sheldon
Mr. Sheldon has been President and Chief Executive Officer of Medicago
since August 2003. He has thirty years of experience in the
pharmaceutical industry, and was named CEO of the Year by the Vaccine
Industry Excellence awards at the World Vaccine Congress in April 2012.
Before joining Medicago, Mr. Sheldon was Vice-President, Sales and
Marketing of Shire Biologics, where he was responsible for
international expansion with European, American and Asian private
partnership agreements and was also responsible for distribution,
customer service, and conflicts of interest and engineering at the
Shire facility. From 1998 to 2000, he was Senior Manager of Commercial
Operations where he successfully managed the approval of a bladder
cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was
Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was
Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992,
he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a
Bachelor's degree in agricultural sciences from Université Laval,
Québec City and a Bachelor's of science degree with honors in
biological sciences from the University of East Anglia, Norwich,
England.
About Jacques Simoneau
Dr. Jacques Simoneau is a corporate director with a comprehensive
experience in venture capital and private equity. Prior to joining
Gestion Univalor L.P. as President and Chief Executive Officer, he was
Executive Vice President, Investments of the Business Development Bank
of Canada ("BDC"). In that capacity, he was responsible for the venture
capital and subordinate financing portfolios. Prior to that, he was
President and CEO of Hydro-Québec CapiTech Inc., Senior Vice-President
of the Fonds de solidarité FTQ and CEO of Société Innovatech du sud du Québec. He also held executive positions at Advanced Scientific Computing and
Alcan. Dr. Simoneau is a director of Transat A.T., a public $3.5
billion international holiday travel company, of Azimut Exploration, a
public Canadian mineral exploration company, and of Sustainable
Development Technology Canada. He serves on the scientific committee of
the Centre québécois de recherche et de développementde l'aluminium and on the University of Montréal's Faculty of Medicine's advisory
committee. Dr. Simoneau was a member of the Conseil de la science et de la technologie duQuébec from 2004 to 2011, and was also director of three other public
companies and 14 private companies between 1995 and now. Jacques
Simoneau is a mechanical engineer and holds a M.Sc. from Université
Laval and a Ph.D. from Queen's University. He is a member of the Ordre des ingénieursdu Québec, of Professional Engineers Ontario and he is certified ICD.D by the
Institute of Corporate Directors.
About DiagnoCure
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Corporation has also granted a worldwide exclusive
license agreement to Gen-Probe, now a wholly-owned subsidiary of
Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using PCA3,
DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA®
PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and the United States. For more
information, visit www.diagnocure.com.
Forwardlooking statements
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.